Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.18 USD

14.18
1,059,347

+0.37 (2.68%)

Updated Jul 25, 2024 10:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

IMV to Develop Vaccine Candidate Against COVID-19, Shares Up

IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

Emergent (EBS) Begins Development of Treatments for COVID-19

Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.

Emergent BioSolutions Collaborates for Coronavirus Vaccine

Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.

Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View

Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.

AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down

AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

Catabasis (CATB) Partners with UK-Based Charity for DMD Study

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

EBS vs. ILMN: Which Stock Is the Better Value Option?

EBS vs. ILMN: Which Stock Is the Better Value Option?

Incyte's Application for Pemigatinib Gets EMA's Validation

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

Nalak Das headshot

5 Top Value Picks to Counter Recent Stock Market Softness

The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.

Emergent Biosolutions (EBS) Down 4.4% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EBS or ILMN: Which Is the Better Value Stock Right Now?

EBS vs. ILMN: Which Stock Is the Better Value Option?

Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

Company News For Sep 4, 2019

Companies in the news are: CONN, MDCO, EBS and RCL

Emergent Biosolutions (EBS) Down 0.9% Since Last Earnings Report: Can It Rebound?

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.